What Is Insider Trading Activity Like At Synergy Pharmaceuticals Inc. (SGYP)?

Marco Green
November 14, 2017

The most recent bid on the stock was registered at $2.44.

About 16.89M shares traded or 170.24% up from the average. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 24.44% since November 14, 2016 and is uptrending. It has outperformed by 7.74% the S&P500. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. Therefore 55% are positive. Synergy Pharmaceuticals had 31 analyst reports since August 25, 2015 according to SRatingsIntel. The Beta for the stock stands at 1.34. The stock of Hammerson plc (LON:HMSO) has "Neutral" rating given on Tuesday, April 18 by Goldman Sachs. The stock has "Buy" rating by Liberum Capital on Friday, January 22. Janney Montgomery Scott Lc holds 35,500 shares. The firm has "Underperform" rating given on Monday, August 24 by Jefferies.

Investors sentiment decreased to 1.49 in 2017 Q2. State Street Corp now owns 12,626,115 shares of the biopharmaceutical company's stock valued at $58,841,000 after buying an additional 6,342,446 shares in the last quarter. 20 funds opened positions while 59 raised stakes. The share last price represents downtick move of -61.96% in value from company's 52-Week high price and shows 6.25% above change in value from its 52-Week low price. Alliancebernstein Ltd Partnership owns 339,330 shares or 0% of their USA portfolio. It has ditched 4.36 million shares.

Williams Jones & Associates Ltd Co owns 11,000 shares.

FCAU institutional proprietorship is held at 0% while insider possession was 0%. Credit Suisse Ag owns 402,894 shares. Nationwide Fund invested in 312,811 shares. Credit Agricole S A reported 4,497 shares or 0% of all its holdings.

Breaking Down: Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has hit extreme technical weakness - watch the stochastics and technical oscillators for any kind of momentum signals if you are looking for a turnaround.

"Merck shares the International Diabetes Federation's vision of promoting diabetes care and prevention worldwide, and we are committed to helping improve the lives of people living with or at risk of type 2 diabetes", said Belén Garijo, M.D., member of the Executive Board and CEO Healthcare at Merck. Exane Derivatives stated it has 7,483 shares. Creative Planning accumulated 151,705 shares.

US stocks were lower in morning trading on Monday as uncertainty over a USA tax reform deal and GE's dismal outlook hit investor sentiment. After this purchase, 30,444 common shares of SGYP are directly owned by the insider, with total stake valued at $82,808. It also reduced Childrens Pl Inc (NASDAQ:PLCE) stake by 10,482 shares and now owns 25,329 shares.

Jim Van Meerten's Daily Stock Picks highlights stocks you might want to consider for your portfolio, with Jim's editorials about current events and stock market commentary. Shares for $19,967 were bought by JACOB GARY S.

The average Wall Street analyst rating for Synergy Pharmaceuticals Inc.is Strong Buy, according to the average of 4 analyst scores. Synergy Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $8.39.

According to data from Finviz's Research, The price target set for the stock is $7.90 and this sets up an interesting set of potential movement for the stock. "(SGYP) Given a $13.00 Price Target by Canaccord Genuity Analysts" was reported by StockNewsTimes and is the property of of StockNewsTimes. As per Friday, December 18, the company rating was downgraded by Citigroup.

Examining Institutional Ownership at Synergy Pharmaceuticals Inc. Cantor Fitzgerald has "Buy" rating and $1100 target. Rodman & Renshaw maintained Synergy Pharmaceuticals Inc (NASDAQ:SGYP) rating on Friday, December 23. The stock's price to sales ratio for trailing twelve months is 89.09 and price to book ratio for the most recent quarter is N/A, whereas price to cash per share for the most recent quarter are 9.50. The firm earned "Buy" rating on Thursday, August 10 by H.C. Wainwright.

Hammerson plc is a real estate investment trust. It has a 9.51 P/E ratio. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER